TG Therapeutics, Inc. (TGTX)

NASDAQ: TGTX · IEX Real-Time Price · USD
5.15
0.10 (1.98%)
May 27, 2022 11:17 AM EDT - Market open
Market Cap743.84M
Revenue (ttm)7.91M
Net Income (ttm)-326.49M
Shares Out144.43M
EPS (ttm)-2.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,076,605
Open5.07
Previous Close5.05
Day's Range4.74 - 5.19
52-Week Range4.73 - 41.00
Beta2.24
AnalystsBuy
Price Target19.96 (+287.6%)
Earnings DateMay 23, 2022

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymph...

IndustryBiotechnology
IPO DateDec 14, 1995
CEOMichael Weiss
Employees286
Stock ExchangeNASDAQ
Ticker SymbolTGTX
Full Company Profile

Financial Performance

In 2021, TGTX's revenue was $6.69 million, an increase of 4,300.66% compared to the previous year's $152,000. Losses were -$348.10 million, 24.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for TGTX stock is "Buy." The 12-month stock price forecast is 19.96, which is an increase of 287.57% from the latest price.

Price Target
$19.96
(287.57% upside)
Analyst Consensus: Buy
Stock Forecasts

News

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Scler...

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral and two poster presentations, highlighting data fr...

1 day ago - GlobeNewsWire

Time to Weed Your Holdings and Upgrade Your Portfolio

With the stock market down 18% from its peak as of May 20, now is a good time for a portfolio upgrade.

Other symbols:ALNYBXPNEESPLKZS
4 days ago - GuruFocus

TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET

1 week ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX

NEW YORK , May 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX). Such investors are advi...

2 weeks ago - PRNewsWire

5 Graham's Lost Formula Biotech Stocks to Consider for May

After a brutal month in April, U.S. market indexes were lower on Tuesday as investors await the Federal Open Market Committee's decision on interest rates.

Other symbols:MRNANGMREGNSGEN
3 weeks ago - GuruFocus

Will TG Therapeutics (TGTX) Report Negative Q1 Earnings? What You Should Know

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

TG Therapeutics to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference

Fireside chat scheduled for Thursday, April 28, 2022 at 12:30 PM ET Fireside chat scheduled for Thursday, April 28, 2022 at 12:30 PM ET

1 month ago - GlobeNewsWire

TG Therapeutics (TGTX) Withdraws FDA Submission, Stock Down

TG Therapeutics (TGTX) voluntarily withdraws regulatory application seeking approval for the combination regimen, ublituximab plus Ukoniq. It also withdraws Ukoniq from sale in approved indications.

1 month ago - Zacks Investment Research

Despite Price Cut, HC Wainwright Keeps Buy Rating On TG Therapeutics - Read Why

TG Therapeutics Inc's (NASDAQ: TGTX) shares are plunging after new data showed that ublituximab /Ukoniq showed an elevated risk of death in the phase 3 Unity combo trial for chronic lymphocytic leukemia...

1 month ago - Benzinga

TG Therapeutics to pull FDA submission for oncology drug; shares slid 24%

Shares of TG Therapeutics Inc. TGTX, -21.85% tumbled 24.2% in trading on Monday following the company's announcement on Friday that it had withdrawn an application to get Food and Drug Administration ap...

1 month ago - Market Watch

Why TG Therapeutics Stock Is Plunging Today

TG Therapeutics Inc (NASDAQ: TGTX) shares are trading significantly lower Monday morning after the company announced it has voluntarily withdrawn the pending Biologics License Application/supplemental N...

1 month ago - Benzinga

TG Therapeutics Retracts FDA Request For Ublituximab / Ukoniq Combo In Blood Cancers

TG Therapeutics Inc's (NASDAQ: TGTX) new data showed that ublituximab /Ukoniq, dubbed U2, had an elevated risk of death in the phase 3 Unity combo trial or chronic lymphocytic leukemia (CLL) and small l...

1 month ago - Benzinga

TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL

Company voluntarily withdraws UKONIQ ® from sale for approved indications of relapsed/refractory MZL and FL Company to host conference call, Monday, April 18, 2022 at 8:30 AM ET NEW YORK, April 15, 2022...

1 month ago - GlobeNewsWire

5 Key FDA Decisions Could Affect Drug Stocks

If readouts on clinical trials can impact the stocks of pharma companies, the Food and Drug Administration (FDA) decisions on whether or not specific drugs are approved can affect not only the stock pri...

Other symbols:AMLXBIIBBLUEBMYGILD
1 month ago - GuruFocus

TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multipl...

NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing for...

1 month ago - GlobeNewsWire

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Scler...

NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of...

1 month ago - GlobeNewsWire

TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting

FDA schedules ODAC meeting for April 22, 2022 FDA schedules ODAC meeting for April 22, 2022

2 months ago - GlobeNewsWire

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Scler...

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral and three poster presentations, highlighting dat...

2 months ago - GlobeNewsWire

FDA Pushes TG Therapeutics' Ublituximab / Ukoniq Combo Therapy Applications In Blood Cancer Settings

The FDA has extended the review period of TG Therapeutics Inc's (NASDAQ: TGTX) biologics license application and supplemental New Drug Application for ublituximab in combination with Ukoniq (umbralisib)...

2 months ago - Benzinga

TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patien...

FDA sets updated PDUFA goal date of June 25, 2022 FDA sets updated PDUFA goal date of June 25, 2022

2 months ago - GlobeNewsWire

TG Therapeutics (TGTX) Reports Q4 Loss, Lags Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -12.90% and 76.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results

Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET

2 months ago - GlobeNewsWire

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Scler...

NEW YORK, Feb. 25, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) ...

3 months ago - GlobeNewsWire

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update

Conference call to be held Tuesday, March 1, 2022 at 8:30 AM ET Conference call to be held Tuesday, March 1, 2022 at 8:30 AM ET

3 months ago - GlobeNewsWire

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Scler...

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) --  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating...

3 months ago - GlobeNewsWire